PRF Technologies Receives FDA Clearance for OcuRing™-K Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2026
0mins
Should l Buy PRFX?
Source: Newsfilter
- FDA Milestone: PRF Technologies' OcuRing™-K has received IND clearance from the FDA, marking a significant advancement in the company's ophthalmic drug delivery strategy, with plans to initiate a multi-center Phase II clinical trial in the second half of 2026 to evaluate pain reduction and inflammation control.
- Innovative Treatment: OcuRing™-K is a bio-erodible intraocular ring designed to deliver ketorolac through a single intraoperative application, potentially eliminating the need for complex post-surgical eye drop regimens, thereby simplifying patient recovery and improving treatment consistency.
- Addressing Market Needs: Cataract surgery is one of the most commonly performed procedures globally, and PRF Technologies' OcuRing™-K aims to enhance drug delivery consistency and reduce dosing burdens, which could significantly improve patient adherence to post-operative care.
- Strategic Platform Expansion: Through its majority ownership of LayerBio, PRF Technologies is building a differentiated ophthalmic platform that may support various applications, including other NSAIDs, steroids, and anti-VEGF products, thereby enhancing the company's long-term value proposition in the healthcare sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRFX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRFX
About PRFX
PRF Technologies Ltd is an Israel-based company engaged primarily in pharmaceutical sector. The Company is a producer of speciality pharmaceuticals as well as energy analytics powered by artificial intelligence (AI). The Firm develops reformulated and sustained‑release drug‑delivery platforms that combine proven generic medicines with proprietary extended‑release systems to improve patient outcomes. One of the Company's products is PRF‑110 - a ropivacaine‑based formulation designed to deliver localised, extended postoperative analgesia. The Company also advances OcuRingTD, a bio‑erodible drug‑release ring integrated with intraocular lenses for continuous delivery of medications in cataract surgery.In the energy analytics sector the Company operates DeepSolar platform that provides AI‑powered monitoring, forecasting, and optimisation tools for solar asset performance.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PRF Technologies Receives FDA Clearance for OcuRing™-K Clinical Trial
- FDA Milestone: PRF Technologies' OcuRing™-K has received IND clearance from the FDA, marking a significant advancement in the company's ophthalmic drug delivery strategy, with plans to initiate a multi-center Phase II clinical trial in the second half of 2026 to evaluate pain reduction and inflammation control.
- Innovative Treatment: OcuRing™-K is a bio-erodible intraocular ring designed to deliver ketorolac through a single intraoperative application, potentially eliminating the need for complex post-surgical eye drop regimens, thereby simplifying patient recovery and improving treatment consistency.
- Addressing Market Needs: Cataract surgery is one of the most commonly performed procedures globally, and PRF Technologies' OcuRing™-K aims to enhance drug delivery consistency and reduce dosing burdens, which could significantly improve patient adherence to post-operative care.
- Strategic Platform Expansion: Through its majority ownership of LayerBio, PRF Technologies is building a differentiated ophthalmic platform that may support various applications, including other NSAIDs, steroids, and anti-VEGF products, thereby enhancing the company's long-term value proposition in the healthcare sector.
See More
PainReform Reports Significant Reduction in FY 2025 Net Loss
- Net Loss Reduction: PainReform reported a net loss of approximately $4.8 million for FY 2025, significantly down from $14.6 million in FY 2024, indicating positive progress in cost control and operational efficiency.
- Cash Position: As of December 31, 2025, PainReform held approximately $4.1 million in cash and cash equivalents, demonstrating a solid liquidity position that can support future operations and growth initiatives.
- Financial Income Growth: The financial income for FY 2025 was $108,000, up from approximately $93,000 in FY 2024, reflecting improvements in investment returns that may lay the groundwork for future profitability.
- Future Outlook: With the reduction in net loss and improved cash flow, PainReform is positioned for better financial performance in the future, enhancing investor confidence and supporting potential business expansion.
See More
PRF Technologies Partners with EDF for Solar Analytics Agreement
- Strategic Partnership: PRF Technologies' DeepSolar unit has signed a solar analytics services agreement with a subsidiary of EDF Group, marking a new phase for its utility-scale solar power plant in Israel and expected to create new commercial revenue opportunities for the company.
- Technical Due Diligence Initiated: Under the agreement, DeepSolar has commenced a technical due diligence engagement, analyzing historical and operational data to support an independent technical review of the solar asset, thereby enhancing transparency and decision-making efficiency in asset management.
- Smart TDD Service Implementation: DeepSolar's Smart TDD service is designed to support multiple use cases across the solar asset lifecycle through analytics-driven methodologies, helping clients identify potential defects and optimize asset performance during acquisition and performance assessments.
- Growing Market Demand: PRF Technologies' Chairman Ehud Geller noted that the increasing demand for technical due diligence and analytics services among large solar operators illustrates the growing commercial interest in DeepSolar's offerings, indicating significant growth potential for the company in the renewable energy sector.
See More
PRF Technologies Signs SaaS Agreement with Shikun & Binui Energy for Solar Analytics
- SaaS Agreement Signed: PRF Technologies has entered into a software-as-a-service (SaaS) agreement with Shikun & Binui Energy to deploy DeepSolar™ at the 71 MW Satu Mare photovoltaic site in Romania, enhancing operational visibility and supporting proactive asset management throughout the project's lifecycle.
- Commercial Deployment: This agreement signifies a step forward in the commercial rollout of DeepSolar, distinguishing it from previous pilot programs and indicating the company's growing capability to support utility-scale solar plant operations, which is expected to improve client decision-making efficiency.
- Market Expansion: The deployment at Satu Mare reflects Shikun & Binui Energy's ongoing expansion in European renewable energy markets, particularly in Romania, further solidifying its competitive position in international markets.
- Technological Innovation: PRF Technologies has also launched the Smart TDD technical due diligence solution to support solar asset transactions and lifecycle performance assessments, enhancing DeepSolar's product stack and demonstrating the company's technological leadership in solar analytics.
See More
PRF TECHNOLOGIES LTD - INSTALLATION OF DEEPSOLAR AT 71 MW FACILITY IN ROMANIA
Deployment of Deep Solar Technology: A new deep solar technology has been deployed at a 71 MW site in Romania, marking a significant advancement in renewable energy solutions.
Impact on Renewable Energy Sector: This deployment is expected to enhance the efficiency and sustainability of solar energy production in the region, contributing to Romania's energy goals.
See More
Rapt Therapeutics Acquired by GSK for $58 per Share, Valuing at $2.2 Billion
- Acquisition Deal: GSK has agreed to acquire Rapt Therapeutics for $58 per share, representing an estimated total equity value of $2.2 billion, which will significantly enhance GSK's market position in the biopharmaceutical sector.
- Stock Surge: Rapt Therapeutics' shares jumped 63.4% to $57.36 in pre-market trading, reflecting a positive market reaction to the acquisition, which may attract more investor interest in the company.
- Market Impact: This acquisition not only increases shareholder value for Rapt but may also prompt other biotech firms to consider similar strategic acquisitions to enhance their competitiveness and market share.
- Industry Outlook: With GSK's acquisition, Rapt's product development process is expected to accelerate, potentially leading to faster drug launches and further solidifying GSK's leadership position in the innovative pharmaceuticals market.
See More
PRF Technologies Receives FDA Clearance for OcuRing™-K Clinical Trial
- FDA Milestone: PRF Technologies' OcuRing™-K has received IND clearance from the FDA, marking a significant advancement in the company's ophthalmic drug delivery strategy, with plans to initiate a multi-center Phase II clinical trial in the second half of 2026 to evaluate pain reduction and inflammation control.
- Innovative Treatment: OcuRing™-K is a bio-erodible intraocular ring designed to deliver ketorolac through a single intraoperative application, potentially eliminating the need for complex post-surgical eye drop regimens, thereby simplifying patient recovery and improving treatment consistency.
- Addressing Market Needs: Cataract surgery is one of the most commonly performed procedures globally, and PRF Technologies' OcuRing™-K aims to enhance drug delivery consistency and reduce dosing burdens, which could significantly improve patient adherence to post-operative care.
- Strategic Platform Expansion: Through its majority ownership of LayerBio, PRF Technologies is building a differentiated ophthalmic platform that may support various applications, including other NSAIDs, steroids, and anti-VEGF products, thereby enhancing the company's long-term value proposition in the healthcare sector.
See More
PainReform Reports Significant Reduction in FY 2025 Net Loss
- Net Loss Reduction: PainReform reported a net loss of approximately $4.8 million for FY 2025, significantly down from $14.6 million in FY 2024, indicating positive progress in cost control and operational efficiency.
- Cash Position: As of December 31, 2025, PainReform held approximately $4.1 million in cash and cash equivalents, demonstrating a solid liquidity position that can support future operations and growth initiatives.
- Financial Income Growth: The financial income for FY 2025 was $108,000, up from approximately $93,000 in FY 2024, reflecting improvements in investment returns that may lay the groundwork for future profitability.
- Future Outlook: With the reduction in net loss and improved cash flow, PainReform is positioned for better financial performance in the future, enhancing investor confidence and supporting potential business expansion.
See More
PRF Technologies Partners with EDF for Solar Analytics Agreement
- Strategic Partnership: PRF Technologies' DeepSolar unit has signed a solar analytics services agreement with a subsidiary of EDF Group, marking a new phase for its utility-scale solar power plant in Israel and expected to create new commercial revenue opportunities for the company.
- Technical Due Diligence Initiated: Under the agreement, DeepSolar has commenced a technical due diligence engagement, analyzing historical and operational data to support an independent technical review of the solar asset, thereby enhancing transparency and decision-making efficiency in asset management.
- Smart TDD Service Implementation: DeepSolar's Smart TDD service is designed to support multiple use cases across the solar asset lifecycle through analytics-driven methodologies, helping clients identify potential defects and optimize asset performance during acquisition and performance assessments.
- Growing Market Demand: PRF Technologies' Chairman Ehud Geller noted that the increasing demand for technical due diligence and analytics services among large solar operators illustrates the growing commercial interest in DeepSolar's offerings, indicating significant growth potential for the company in the renewable energy sector.
See More
PRF Technologies Signs SaaS Agreement with Shikun & Binui Energy for Solar Analytics
- SaaS Agreement Signed: PRF Technologies has entered into a software-as-a-service (SaaS) agreement with Shikun & Binui Energy to deploy DeepSolar™ at the 71 MW Satu Mare photovoltaic site in Romania, enhancing operational visibility and supporting proactive asset management throughout the project's lifecycle.
- Commercial Deployment: This agreement signifies a step forward in the commercial rollout of DeepSolar, distinguishing it from previous pilot programs and indicating the company's growing capability to support utility-scale solar plant operations, which is expected to improve client decision-making efficiency.
- Market Expansion: The deployment at Satu Mare reflects Shikun & Binui Energy's ongoing expansion in European renewable energy markets, particularly in Romania, further solidifying its competitive position in international markets.
- Technological Innovation: PRF Technologies has also launched the Smart TDD technical due diligence solution to support solar asset transactions and lifecycle performance assessments, enhancing DeepSolar's product stack and demonstrating the company's technological leadership in solar analytics.
See More
PRF TECHNOLOGIES LTD - INSTALLATION OF DEEPSOLAR AT 71 MW FACILITY IN ROMANIA
Deployment of Deep Solar Technology: A new deep solar technology has been deployed at a 71 MW site in Romania, marking a significant advancement in renewable energy solutions.
Impact on Renewable Energy Sector: This deployment is expected to enhance the efficiency and sustainability of solar energy production in the region, contributing to Romania's energy goals.
See More
Rapt Therapeutics Acquired by GSK for $58 per Share, Valuing at $2.2 Billion
- Acquisition Deal: GSK has agreed to acquire Rapt Therapeutics for $58 per share, representing an estimated total equity value of $2.2 billion, which will significantly enhance GSK's market position in the biopharmaceutical sector.
- Stock Surge: Rapt Therapeutics' shares jumped 63.4% to $57.36 in pre-market trading, reflecting a positive market reaction to the acquisition, which may attract more investor interest in the company.
- Market Impact: This acquisition not only increases shareholder value for Rapt but may also prompt other biotech firms to consider similar strategic acquisitions to enhance their competitiveness and market share.
- Industry Outlook: With GSK's acquisition, Rapt's product development process is expected to accelerate, potentially leading to faster drug launches and further solidifying GSK's leadership position in the innovative pharmaceuticals market.
See More
